Merck & Co.

Related Articles

Pharmaceuticals

FDA Approves Liptruzet (ezetimibe and atorvastatin), a to Help Lower LDL Cholesterol
Results from HPS2-THRIVE Show Increase in Adverse Side Effects of Niacin Combined With Statin Therapy
CETP Inhibitor Met Safety, Efficacy Endpoints in Heart Disease Patients
Companies Partner to Produce Generic Zetia
Factor Xa Inhibitor Reduced Bleeding Compared to Warfarin in AF Patients
Trial Evaluates New Anti-Platelet in Preventing Cardiovascular Events
Merck, Portola to Develop Oral Anticoagulant for Cardiovascular Disease
Merck, Cardiome Sign License Agreement for Investigational Drug for Treatment of Atrial Fibrillation
Iroko Acquires Rights to Merck Drug for PTCA Patients
Liptruzet

Clinical Trial/Study

CETP Inhibitor Met Safety, Efficacy Endpoints in Heart Disease Patients
Factor Xa Inhibitor Reduced Bleeding Compared to Warfarin in AF Patients
Trial Evaluates New Anti-Platelet in Preventing Cardiovascular Events

Cardiac Rhythm Management Therapy

Merck, Cardiome Sign License Agreement for Investigational Drug for Treatment of Atrial Fibrillation

Angiographic Catheter

Iroko Acquires Rights to Merck Drug for PTCA Patients